Oncology and Hematology

129-144 of 612

Axatilimab for cGVHD: Assessing Organ-Specific Responses in AGAVE-201
Axatilimab for cGVHD: Assessing Organ-Specific Responses in AGAVE-201
Project Oncology®
Axatilimab for cGVHD: Assessing Organ-Specific Responses in AGAVE-201
- Charles Turck, PharmD, BCPS, BCCCP
- Shernan Holtan, MD
- Alicia Lieberman, MD, MS
Obesity and Cancer Screening: National Trends and Disparities Revealed
Obesity and Cancer Screening: National Trends and Disparities Revealed
Clinician's Roundtable
Obesity and Cancer Screening: National Trends and Disparities Revealed
- Vance Albaugh, MD, PhD
Managing MCL After BTKi Failure: The Expanding Role of CAR T-Cell Therapy
Managing MCL After BTKi Failure: The Expanding Role of CAR T-Cell Therapy
Project Oncology®
Managing MCL After BTKi Failure: The Expanding Role of CAR T-Cell Therapy
- Charles Turck, PharmD, BCPS, BCCCP
- Luhua (Michael) Wang, MD
Advancing MPE Diagnosis and Prognosis: Clinical Value of Biomarker Integration
Advancing MPE Diagnosis and Prognosis: Clinical Value of Biomarker Integration
Clinician's Roundtable
Advancing MPE Diagnosis and Prognosis: Clinical Value of Biomarker Integration
- David Feller-Kopman, MD
Chronic Graft-Versus-Host Disease Care: Evolving Therapeutic Strategies
Chronic Graft-Versus-Host Disease Care: Evolving Therapeutic Strategies
Project Oncology®
Chronic Graft-Versus-Host Disease Care: Evolving Therapeutic Strategies
- Brian P. McDonough, MD, FAAFP
- Doris M. Ponce, MD, MS
Reevaluating Race in Spirometry: Advancing Equity in Pulmonary Risk Assessment
Reevaluating Race in Spirometry: Advancing Equity in Pulmonary Risk Assessment
Project Oncology®
Reevaluating Race in Spirometry: Advancing Equity in Pulmonary Risk Assessment
Modernizing Pulmonary Assessment: Reassessing Race-Neutral Interpretation in Practice
Modernizing Pulmonary Assessment: Reassessing Race-Neutral Interpretation in Practice
Project Oncology®
Modernizing Pulmonary Assessment: Reassessing Race-Neutral Interpretation in Practice
Evaluating Axatilimab in Chronic GVHD: How Prior Therapies Impact Outcomes
Evaluating Axatilimab in Chronic GVHD: How Prior Therapies Impact Outcomes
Project Oncology®
Evaluating Axatilimab in Chronic GVHD: How Prior Therapies Impact Outcomes
- Hallie Blevins, PhD
Adjuvant Pembrolizumab Plus Cisplatin-Based Chemoradiation in Locally Advanced HNSCC: First Results From the Randomized Phase 2b ADRISK Trial
Adjuvant Pembrolizumab Plus Cisplatin-Based Chemoradiation in Locally Advanced HNSCC: First Results From the Randomized Phase 2b ADRISK Trial
Oncology and Hematology
Adjuvant Pembrolizumab Plus Cisplatin-Based Chemoradiation in Locally Advanced HNSCC: First Results From the Randomized Phase 2b ADRISK Trial
- Yungan Tao
Patient-Reported Outcomes From the Phase 3 KEYNOTE-689 Trial of Adding Perioperative Pembrolizumab to Standard of Care in Resectable Locally Advanced HNSCC
Patient-Reported Outcomes From the Phase 3 KEYNOTE-689 Trial of Adding Perioperative Pembrolizumab to Standard of Care in Resectable Locally Advanced HNSCC
Oncology and Hematology
Patient-Reported Outcomes From the Phase 3 KEYNOTE-689 Trial of Adding Perioperative Pembrolizumab to Standard of Care in Resectable Locally Advanced HNSCC
- Yungan Tao
KEYNOTE-717: Randomized Phase 2 Trial of Adding Local Hypofractionated Radiotherapy to Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
KEYNOTE-717: Randomized Phase 2 Trial of Adding Local Hypofractionated Radiotherapy to Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
Oncology and Hematology
KEYNOTE-717: Randomized Phase 2 Trial of Adding Local Hypofractionated Radiotherapy to Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
- Prof. Markus Hecht
Cohort 9 of the Phase 2 EV-202 Trial: First-Line Enfortumab Vedotin Plus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Cohort 9 of the Phase 2 EV-202 Trial: First-Line Enfortumab Vedotin Plus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Oncology and Hematology
Cohort 9 of the Phase 2 EV-202 Trial: First-Line Enfortumab Vedotin Plus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- Paul L Swiecicki, MD
Amivantamab Monotherapy or in Combination With Paclitaxel in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: OrigAMI-4 Study Results
Amivantamab Monotherapy or in Combination With Paclitaxel in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: OrigAMI-4 Study Results
Oncology and Hematology
Amivantamab Monotherapy or in Combination With Paclitaxel in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: OrigAMI-4 Study Results
- Kevin J Harrington, PhD, FRCP, FRCR, FRSB
Evaluating Patient and Clinician-Reported Responses to Axatilimab in cGVHD
Evaluating Patient and Clinician-Reported Responses to Axatilimab in cGVHD
Project Oncology®
Evaluating Patient and Clinician-Reported Responses to Axatilimab in cGVHD
- Brian P. McDonough, MD, FAAFP
- Christopher Graham, MD
Advancing Precision Medicine in NSCLC: Real-World Impact of the PREDICT Initiative
Advancing Precision Medicine in NSCLC: Real-World Impact of the PREDICT Initiative
Project Oncology®
Advancing Precision Medicine in NSCLC: Real-World Impact of the PREDICT Initiative
Impacts of Multidisciplinary Tumor Boards and Surgery Integration on NSCLC Survival
Impacts of Multidisciplinary Tumor Boards and Surgery Integration on NSCLC Survival
Project Oncology®
Impacts of Multidisciplinary Tumor Boards and Surgery Integration on NSCLC Survival